FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Ocriplasmin (Jetrea) Injection
Status: Discontinuation
»Therapeutic Categories: Ophthalmology

Thrombogenics, Inc. (New 04/24/2020)

Company Contact Information:
855-879-5387

Presentation Posting Date Related Information
1.25 mg/ml (NDC 24856-002-01) 04/24/2020 ThromboGenics has decided for business reasons to discontinue manufacture of the drug product for the United States.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English